Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease
Open Access
- 13 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Parkinson's Disease
- Vol. 6 (1), 1-13
- https://doi.org/10.1038/s41531-020-00134-x
Abstract
The catecholamine neurotransmitter dopamine has the potential to act as an endogenous neurotoxin when its vesicular sequestration is dysregulated. Despite postmortem analyses from patients with Parkinson’s disease that demonstrate decreased vesicular sequestration of dopamine with a corresponding increase in dopamine metabolism, dopamine’s contribution to nigrostriatal dopaminergic degeneration in Parkinson’s disease has been debated. Here, we present a new in vivo model demonstrating the induction of Parkinson’s disease-associated pathogenic mechanisms of degeneration resulting from acquired dysregulation of dopamine sequestration in nigrostriatal dopaminergic neurons in adult rats. Utilizing adeno-associated virus (serotype 2), viral-mediated small-hairpin RNA interference of endogenous vesicular monoamine transporter 2 (VMAT2) expression resulted in a loss of VMAT2 protein expression in transduced dopaminergic cell bodies in the substantia nigra with a corresponding loss of VMAT2 protein within the striatal terminals. The loss of VMAT2 resulted in an accumulation of cytosolic dopamine and subsequent increased dopamine metabolism, deficits in dopamine-mediated behaviors, and degeneration of nigrostriatal dopaminergic neurons that was rescued through reintroduction of exogenous VMAT2, demonstrating that the toxicity was specific to the loss of VMAT2. Analysis of parkinsonian pathogenic mechanisms of degeneration identified oxidative damage, activation of Parkinson’s disease-associated kinase LRRK2, and the formation of aberrant α-synuclein. This model demonstrates that a progressive acquired loss of VMAT2 expression in adulthood is sufficient to induce Parkinson’s disease-associated pathogenic mechanisms of degeneration and provides a new model to further investigate the consequences of cytosolic dopamine.Funding Information
- Michael J. Fox Foundation for Parkinson’s Research (Path to PD)
- Friends and Family of Sean Logan, University of Pittsburgh Medical School Research Funds
- University of Pittsburgh (Andrew Mellon Predoctoral Fellowship)
This publication has 70 references indexed in Scilit:
- Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s diseaseNeurobiology of Aging, 2013
- Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53Journal of Biological Chemistry, 2012
- Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceNeurobiology of Disease, 2010
- The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neuronsNeurobiology of Disease, 2010
- A Biochemical and Functional Protein Complex Involving Dopamine Synthesis and Transport into Synaptic VesiclesOnline Journal of Public Health Informatics, 2010
- Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cellsNeurobiology of Disease, 2009
- Protein Reactivity of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite, Is Dependent on Both the Aldehyde and the CatecholChemical Research in Toxicology, 2009
- Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra NeuronsNeuron, 2009
- Pesticide exposure and risk of Parkinson's disease: A family-based case-control studyBMC Neurology, 2008
- Dopamine-modified α-synuclein blocks chaperone-mediated autophagyJCI Insight, 2008